37K shares changed hands on Tuesday. Overall, volume was down 76.62% under the stocks normal daily volume.
Investors are more bullish on the company recently if you pay attention to the fall in short interest. The firm saw a fall in short interest of -7.94% as of October 13, 2017 from the last reporting period. Short interest fell 59,896 over that period. Days to cover decreased -17.0 to 3.0 and the short interest percentage is 0.04% as of October 13.
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) has been the object of insider selling activity recently. David Y. Liu, Chief Scientific Officer sold $52,500 worth of shares at an average price of $15.00 on Mon the 28th. That brings Liu’s holdings to $30,000 as reported to the SEC. Chief Medical Officer Richard S. Shames sold 1,512 shares at an average price of $17.00 on Tue the 29th. The Chief Medical Officer now owns $31,705 of the stock per an SEC filing yesterday.
Chief Medical Officer Richard S. Shames let go of 3,687 shares at an average price of $14.31 on September 12th. That brings the Chief Medical Officer’s holdings to $0 as recorded in a recent Form 4 SEC filing.
Here are a few substantial investment firms who have updated their positions. As of the end of the quarter Bank Of Montreal /can/ had sold a total of 24 shares trimming its position 4.6%. The value of the company’s investment in Protagonist Therapeutics, Inc. increased from $6,000 to $9,000 increasing 50.0% quarter to quarter.
Equity analyst BTIG Research added the stock to its research portfolio with an initial rating of “Buy”.
In the market the company is trading down from yesterday’s close of $0.00. The stock is trading at $14.97 which is quite a bit below the 50 day moving average which is $16.74 and which is quite a bit above the 200 day moving average of $13.07. The 50 day moving average was down by -10.59% and the 200 day average went up by +14.49%.
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. Its product candidates include PTG-100, which has first-in-class potential as an oral, a4b7 integrin-specific antagonist peptide for the treatment of inflammatory bowel disease (IBD); PTG-200, a gastrointestinal-restricted peptide product candidate for the treatment of IBD; and PTG-300, an injectable hepcidin mimetic peptide for the treatment of iron overload disorders, such as transfusion-dependent b-Thalassemia, hereditary hemochromatosis, and sickle cell disease. The company was founded in 2006 and is headquartered in Milpitas, California..